Fulminant hepatic failure due to adenovirus infection is a rare complication following stem cell transplantation. We report this complication in an unrelated bone marrow transplant recipient 30 weeks post-transplant. Treatment with intravenous ribavirin was started within 36 h of admission, but he succumbed to unusually fulminant hepatic failure. Adenovirus type 2 was isolated from stool surveillance samples and from post-mortem liver samples. Adenovirus DNA was detected by PCR in blood and sputum samples at admission and was identified in post-mortem liver tissue by electron microscopy. Implications of the failure of ribavirin therapy are discussed. Keywords: adenovirus; bone marrow transplantation; liver failure; ribavirin Adenovirus infections have been increasingly reported in marrow transplant recipients over the past few years. [1] [2] [3] This is probably attributable to the increase in intensity of immunosuppression and the use of T cell depletion in unrelated donor transplants. Although effective treatment strategies have evolved for cytomegalovirus infection in stem cell transplant recipients, little progress has been made in the treatment of adenovirus infection. Ribavirin, a broad spectrum antiviral agent has often been used in adenovirus disease in stem cell transplant recipients with variable results. [4] [5] [6] [7] We report an uncommon presentation of adenovirus infection in an unrelated bone marrow transplant recipient with failure of ribavirin therapy and briefly discuss its implications.
irradiation (1440 cGy) as the conditioning regimen, together with Campath-1G antibody (10 mg/day) from day −5 to day +4. GVHD prophylaxis was cyclosporin A and short course methotrexate. The patient also received prophylactic aciclovir, fluconazole and ciprofloxacin. He had evidence of neutrophil engraftment by day +19. Grade 2-3 acute GVHD of the skin developed and was treated with intravenous methylprednisolone (5 mg/kg) followed by oral prednisolone (100 mg/day). At his discharge on day +28 he was on tapering doses of prednisolone. During this period he had stomatitis related to herpes simplex virus which responded to valaciclovir and also an episode of respiratory illness of unproven aetiology. After initial good engraftment, there was a fall in neutrophil and platelet counts. This was associated with normal marrow cellularity. The pancytopenia was thought to be autoimmune or related to GVHD. This was treated with prednisolone, intravenous immunoglobulin, azathioprine and G-CSF with little success. Parvovirus B19 and human herpesvirus-6 infections were excluded. Recurrent herpes simplex stomatitis unresponsive to valaciclovir became a problem. Thirty weeks post-transplant, he was admitted unwell and with rapidly worsening jaundice. On examination he had deep jaundice and mild tenderness over the right hypochondrium. Investigations showed haemoglobin 8.6 g/dl, white cell count 0.7 × 10 9 /l, platelets 14 × 10 9 /l, INR 1.0, bilirubin 148 mol/l, alkaline phosphatase 1469 /l (normal 30-200), aspartate aminotransferase 2488 /l, albumin 24 g/l. Bacterial and fungal cultures from blood, urine, sputum and stool were negative. Chest X-ray was normal. Serology for current infection with hepatitis A, B and C viruses was negative, as was PCR for CMV DNA on whole blood. Throat swab and sputum were negative for respiratory syncytial virus, influenza A and B and parainfluenza viruses by direct immunofluorescence. Serology for current infection with Chlamydia sp, Toxoplasma gondii, Mycoplasma pneumoniae and parvovirus B19 was negative. Adenovirus type 2 was isolated from a stool surveillance sample obtained a week before the presenting illness and on two consecutive stool samples thereafter. A liver biopsy was not performed due to severe thrombocytopenia and worsening coagulopathy. However, PCR for adenovirus DNA was positive from sputum and blood. In view of his rapid clinical deterioration and a high index of suspicion he was started on intravenous (i.v.) ribavirin (ICN, Basingstoke, UK) 36 h after admission at a loading dose of 35 mg/kg followed by 25 mg/kg every 8 h. In spite of intensive supportive treatment and i.v. ribavirin therapy, he succumbed to progressive hepatocellular failure on the seventh day following admission.
A limited necropsy was performed. Light microscopy of a liver biopsy showed extensive areas of necrosis with sparse inflammatory infiltrate and ill-defined intranuclear inclusions. The liver architecture was preserved with no abnormality in the central veins, portal veins and arteries or bile ductules. Electron microscopy of the liver biopsy tissue ( Figure 1 ) revealed adenovirus particles and adenovirus type 2 was subsequently grown from the liver tissue.
Discussion
In stem cell transplant recipients, adenovirus infections are recognised to have protean manifestations.
1,2 Adenovirus hepatitis is not uncommon, but such fulminant hepatic failure as described in our patient is an unusual presentation of adenovirus infection, only five cases having been reported in the literature. 2, [8] [9] [10] [11] The clinical course in our patient was much more fulminant than the cases previously described. Adenovirus serotypes do not seem to correlate with severity of infection in BMT recipients with the possible exception of type 31 which has the highest fatality rate (69%).
12 Subgenera B (types 7, 11, 34 and 35) are associated mostly with urinary tract infections whereas subgenera C (types 1, 2 and 5) predominate in liver disease without any significant difference in fatality rate. 12 Adenovirus type 5 has been isolated most frequently in patients with hepatitis as well as fulminant hepatic failure, types 1 and 2 being the other serotypes isolated in patients with fulminant hepatic failure. 1, 2, 8, 11, 12 The liver histology in acute adenoviral liver failure is quite characteristic. Random and extensive areas of coagulative necrosis with intranuclear inclusions on a background of normal liver architecture with sparse inflammatory infiltrate as seen in our patient is similar to previous descriptions. 11 Confirmation is obtained either from electron microscopy and virus culture or immunohistochemical staining. The potential causes of post-bone marrow transplant liver disease are numerous and the liver histology is important in making a diagnosis. This is frequently impossible because of coagulation defects and thrombocytopenia precluding liver biopsy. In none of the previous five cases of fulminant adenovirus hepatitis was it possible to obtain antemortem liver tissue. Understandably, no definitive treatment had been attempted in any of these cases. Although we also failed to obtain liver tissue for similar reasons the rapid downhill course led to a presumptive diagnosis of adenovirus disease based on a routine surveillance stool culture and detection of adenovirus DNA in blood and sputum by PCR. This is possibly the first reported patient with fulminant adenovirus hepatitis to be treated with intravenous ribavarin, although without success. The role of ribavirin in adenovirus infection in stem cell transplant recipients is ambiguous. The reported success of ribavirin in adenovirus infections could be related to the site of infection, as most of the successfully treated cases are infections of the respiratory or urinary tracts. 4, 5, 13 Nebulised ribavirin achieves a high concentration in the respiratory tract which is not achievable with intravenous administration. 13 Similarly, 16% of i.v. ribavirin is excreted unchanged in the urine probably accounting for the success in treating adenovirus cystitis or nephritis. 6, 13 Ganciclovir (GCV) is probably less active against adenovirus serotypes, but has been used successfully in adenovirus cystitis.
14 This might again be attributable to higher drug levels in the urinary system as GCV is excreted unchanged in the urine. Thus, the failure of i.v. ribavirin in treating other sites of infection may be related more to the achievement of therapeutic concentrations of the drug at those sites rather than a lack of antiviral activity.
Adenovirus isolates resistant to ribavirin have not been reported to date. Because of the small number of patients treated and lack of information on serotypes in reports, it is difficult to comment if any particular serotype is more susceptible to antiviral drugs. The dose and efficacy of ribavirin in severe liver disease remains unclear. The drug undergoes hepatic metabolism but is not reported to be hepato-toxic. Using ribavirin at doses used by Liles et al 5 for 6 days in presence of liver failure did not lead to any adverse effects.
Another decisive factor in the outcome of ribavirin therapy might be the immune competence of the patient. Two of the largest studies identified moderate to severe GVHD as a risk factor for adenovirus disease.
1, 2 Incidence of adenovirus infections increases three-fold in T cell-depleted transplants. 3 Hromas et al 6 reported failure of ribavarin to clear adenovirus infections from the urinary tract, as well as other sites in three T cell-depleted unrelated allograft recipients. Interestingly, patients who failed to respond to ribavirin either had grade 4 GVHD 7 or were T cell-depleted allograft recipients. 6 Paradoxically, ribavirin itself has immunosuppressive effects, although the clinical relevance is not clear. 12 Current therapeutic strategies for adenovirus infection appear to be inadequate. Other antivirus drugs such as vidarabine 15 and cidofovir, 16 which have been reported to be effective in isolated cases of adenovirus infection are toxic to the marrow, kidneys or the nervous system. 13 Some authors feel that failure of i.v. ribavirin might be due to the delay in initiation of treatment. 7 It is possible that, in parallel with CMV, a pre-emptive treatment strategy with ribavi-rin might be considered in high risk patients using a PCR assay to detect adenovirus DNA in peripheral blood mononuclear cells. 17 Adoptive immunotherapy might be a therapeutic avenue worth further consideration, as in CMV or EBV infections. Having failed to salvage four adenovirus-infected T celldepleted stem cell transplant recipients with i.v. ribavirin, Hromas et al 18 used donor leucocyte infusion (DLI) with success in another such patient. Infusion of cryopreserved autologous PBSC has also been effective for adenovirus cystitis following a CD34-selected autologous PBSC transplant. 19 In a further (unreported) allogeneic stem cell transplant recipient in our institution, persistent adenovirus excretion in the stool was cleared by DLI for relapsed leukaemia. However, the timing of DLI is important as adoptive immunotherapy of this type is more effective at earlier stages of the disease. It is unlikely to be effective for more severe infections, but might be considered as an adjunct to antiviral therapy.
